An award-winning journalist, Derrick has written extensively about user fee negotiations, the FDA budget, FDA travel restrictions and drug advertising compliance. He also was part of the Pink Sheet team covering FDA's first biosimilar advisory committee meetings.
When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball.
Latest From Derrick Gingery
FDA is only mentioned once in the document, and its temporary leadership may not be the reason why.
Pink Sheet reporters and editor discuss the influence of the emergency use authorization on FDA decisions, another twist in the march-in rights debate, and how CBER is not using the real-time oncology review program.
Former FDA Commissioner Stephen Hahn and former CDC Director Robert Redfield said leaders of their agencies and NIH should be selected outside the election schedule. White House task force reviewing political interference with agency science.
Proposed commitment letter language included a look at eliminating REMS, potentially to more clearly outline the process.
Bubble was short-lived, but still could create workload problems for the US FDA as it navigates the end of the coronavirus pandemic.
The oncology branch of the US FDA’s biologics center does not believe RTOR would speed application reviews.